Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept Conversion Trial in Renal Transplantation
2005-005238-11Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of belatacept in kidney allograft rejection (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change in calculated GFR from baseline to 12 months. Started Jan 2007; status: completed.
02
Drugs
belatacept
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2005-005238-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005238-11.